Sweety Mathew is a Senior Regulatory Affairs professional and a Global RA CMC Lead (Rare Diseases) working with Novo Nordisk. She has around 14 years of experience and has a broad expertise across biopharmaceutical drug development (Novel biologics, Biosimilars and peptides (synthetic & recombinant)). With a Cell and Molecular Biology background, the inspiration to join regulatory sciences was drawn from the fact that this function provided an insight on all stages of drug development to life cycle management and being that conduit between the company and the regulators, bridging science and business. Sweety has engaged in successful approvals of several biopharmaceutical drug candidates, from the early stages throughout the life cycle management across multiple therapeutic areas including metabolic disorders, oncology and rare diseases. Prior to joining Novo Nordisk, she was associated with companies such as Biocon Biologics, Biomarin etc. She has been an invited speaker in various international forums sharing regulatory insights. She pursued her postgraduate degree in Bioinformatics and Applied Biotechnology from the University of Westminster, London.